Asset profile
Isatuximab
Monoclonal antibody
Approvedregulatory verdict
Evidence outlook
Approved: Multiple Myeloma
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
73 competitors in this universe: 13 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication.
Unlock with Research ↗
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Isatuximab: this drug | Approved | Monoclonal antibody | CD38 | ||
| Daratumumab | Approved | Monoclonal antibody | CD38 | ||
| BCD-264 | Phase 3 | Monoclonal antibody | CD38 | ||
| CT-P44 | Phase 3 | Monoclonal antibody | CD38 | ||
| HLX15 | Phase 3 | Monoclonal antibody | CD38 | ||
| Mezagitamab | Phase 3 | Monoclonal antibody | CD38 | ||
| QL2109 | Phase 3 | Monoclonal antibody | CD38 | ||
| SCTC21C | Phase 3 | Biologic (subtype unspecified) | CD38 | ||
| SG301 | Phase 3 | Monoclonal antibody | CD38 | ||
| TJ202 | Phase 3 | Monoclonal antibody | CD38 | ||
| CID-103 | Phase 1/2 | Monoclonal antibody | CD38 | ||
| CM313 | Phase 1/2 | Monoclonal antibody | CD38 | ||
| STI-6129 | Phase 1/2 | Antibody–drug conjugate | CD38 | ||
| SAR442085 | Phase 1 | Biologic (subtype unspecified) | CD38 | ||
| Belantamab Mafodotin | Approved | Antibody–drug conjugate | BCMA | ||
| Bortezomib | Approved | Small molecule | Proteasome |
…and 58 more. Research shows the complete landscape.
Research
Unlock with Research ↗Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
vs Daratumumab · Multiple Myelomavs Mezagitamab · Multiple Myelomavs TJ202 · Multiple Myelomavs CID-103 · Multiple Myelomavs CM313 · Multiple Myelomavs SAR442085 · Multiple Myeloma
7 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(44 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (4)
November 2026 (2)
2027 (17)
January 2027 (1)
Phase 2Plasma Cell Myeloma RefractoryRecruiting
Est. primary completion 2027-01-08 · NCT06356571 · CT.gov ↗
What to watch
April 2027 (4)
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2027-04 · NCT05558319 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-04-01 · NCT04835129 · CT.gov ↗
What to watch
Phase 3Plasma Cell MyelomaActive not recruiting
Est. primary completion 2027-04-05 · NCT03319667 · CT.gov ↗
What to watch
Phase 2Smoldering Plasma Cell MyelomaActive not recruiting
Est. primary completion 2027-04-30 · NCT02960555 · CT.gov ↗
What to watch
May 2027 (1)
Phase 1AL AmyloidosisActive not recruiting
Est. primary completion 2027-05-06 · NCT04754945 · CT.gov ↗
What to watch
June 2027 (1)
Phase 2Blood Cancer, Refractory Immune CytopeniasActive not recruiting
Est. primary completion 2027-06-29 · NCT05873205 · CT.gov ↗
What to watch
July 2027 (2)
August 2027 (1)
Phase 2/3Multiple MyelomaRecruiting
Est. primary completion 2027-08 · NCT05665140 · CT.gov ↗
What to watch
September 2027 (1)
Phase 1/2Plasma Cell Myeloma RefractoryRecruiting
Est. primary completion 2027-09-13 · NCT04643002 · CT.gov ↗
What to watch
October 2027 (3)
Phase 2Multiple MyelomaNot yet recruiting
Est. primary completion 2027-10-09 · NCT07789522 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaNot yet recruiting
Est. primary completion 2027-10-09 · NCT07828522 · CT.gov ↗
What to watch
Phase 2Recurrent Plasma Cell Myeloma, Refractory Plasma Cell MyelomaActive not recruiting
Est. primary completion 2027-10-15 · NCT04850599 · CT.gov ↗
What to watch
December 2027 (3)
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-12 · NCT04891809 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2027-12-31 · NCT04558931 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2027-12-31 · NCT05776979 · CT.gov ↗
What to watch
2028 (11)
March 2028 (3)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2028-03 · NCT05272826 · CT.gov ↗
What to watch
Phase 1Multiple MyelomaRecruiting
Est. primary completion 2028-03-25 · NCT05137054 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2028-03-31 · NCT07045909 · CT.gov ↗
What to watch
May 2028 (1)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2028-05-01 · NCT07585760 · CT.gov ↗
What to watch
June 2028 (2)
July 2028 (1)
Phase 4Multiple MyelomaNot yet recruiting
Est. primary completion 2028-07 · NCT07334535 · CT.gov ↗
What to watch
November 2028 (1)
Phase 2Plasma Cell MyelomaEnrolling by invitation
Est. primary completion 2028-11-30 · NCT05669989 · CT.gov ↗
What to watch
December 2028 (3)
Phase 3Multiple MyelomaActive not recruiting
Est. primary completion 2028-12 · NCT06216158 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2028-12-31 · NCT05922501 · CT.gov ↗
What to watch
Phase 2/3Multiple MyelomaNot yet recruiting
Est. primary completion 2028-12-31 · NCT07732712 · CT.gov ↗
What to watch
2029 (5)
January 2029 (1)
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2029-01-11 · NCT07764978 · CT.gov ↗
What to watch
June 2029 (2)
July 2029 (1)
Phase 1/2Multiple MyelomaNot yet recruiting
Est. primary completion 2029-07-01 · NCT07601100 · CT.gov ↗
What to watch
December 2029 (1)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2029-12-01 · NCT04240054 · CT.gov ↗
What to watch
2030 (2)
2032 (1)
November 2032 (1)
Phase 2Smouldering MyelomaRecruiting
Est. primary completion 2032-11 · NCT06762769 · CT.gov ↗
What to watch
2033 (2)
2035 (1)
March 2035 (1)
Phase 2/3Acute Lymphoblastic LeukemiaRecruiting
Est. primary completion 2035-03-15 · NCT06860269 · CT.gov ↗
What to watch
2036 (1)
September 2036 (1)
Phase 1/2Multiple MyelomaNot yet recruiting
Est. primary completion 2036-09-30 · NCT07600151 · CT.gov ↗
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.